This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Léon, C. Articles by Gachet, C. Search for Related Content PubMed PubMed Citation Articles by Léon, C. Articles by Gachet, C. Related Collections Antiplatelets Platelets Animal models of human disease Genetically altered mice

(Circulation. 2001;103:718.)
© 2001 American Heart Association, Inc.

Basic Science Reports

Key Role of the P2Y₁ Receptor in Tissue Factor–Induced Thrombin-Dependent Acute Thromboembolism

Studies in P2Y₁-Knockout Mice and Mice Treated With a P2Y₁ Antagonist

Catherine Léon, PhD; Monique Freund, PhD; Catherine Ravanat, PhD; Anthony Baurand, MSc; Jean-Pierre Cazenave, MD, PhD; Christian Gachet, MD, PhD

From the Institut National de la Santé et de la Recherche Médicale U.311, Etablissement Français du Sang–Alsace, Strasbourg, France.

Correspondence to Dr C. Gachet, INSERM U.311, Etablissement Français du Sang–Alsace (EFS-Alsace), 10, rue Spielmann, BP N^o 36, 67065 Strasbourg Cédex, France. E-mail christian.gachet{at}etss.u-strasbg.fr

Background—ADP plays a key role in hemostasis, acting through 2 platelet receptors: the P2Y₁ receptor and an unidentified P2 receptor, called P2cyc, coupled to adenylyl cyclase inhibition, which is the target of the antiplatelet drug clopidogrel. We showed that the P2Y₁ receptor is an essential cofactor in thrombotic states induced by intravenous infusion of collagen and epinephrine. The aim of the present study was to assess the role of this receptor in thrombin-dependent tissue factor–induced thromboembolism.

Methods and Results—Human thromboplastin was injected intravenously into wild-type or P2Y₁-deficient mice, and the effects on platelet count and mortality were determined and plasma thrombin–antithrombin III (TAT) complexes were quantified. P2Y₁-deficient mice were resistant to the thromboembolism induced by injection of thromboplastin. Whereas the platelet count decreased sharply in wild-type mice, there was no significant drop in platelets in P2Y₁-knockout mice. The platelet consumption in wild-type mice was probably due to thrombin generation, because it was abolished by hirudin. Thromboplastin also led to a rise in TAT complexes in plasma, again reflecting thrombin formation. This effect, however, was less important in P2Y₁-knockout mice than in wild-type mice, indicating that less thrombin was generated in the absence of P2Y₁. Similar results were obtained after intravenous administration of N⁶-methyl-2'-deoxyadenosine-3':5'-bisphosphate, a selective antagonist of the P2Y₁ receptor, to wild-type mice.

Conclusions—Our results demonstrate a role of the P2Y₁ receptor in thrombotic states involving thrombin generation and provide further evidence for the potential relevance of this receptor as a target for antithrombotic drugs.

Key Words: receptors • adenosine diphosphate • thrombosis • drugs • platelets

This article has been cited by other articles:

				B.-S. Ding, N. Hong, J.-C. Murciano, K. Ganguly, C. Gottstein, M. Christofidou-Solomidou, S. M. Albelda, A. B. Fisher, D. B. Cines, and V. R. Muzykantov Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature Blood, February 15, 2008; 111(4): 1999 - 2006. [Abstract] [Full Text] [PDF]

				B. N. Kahner, R. T. Dorsam, S. R. Mada, S. Kim, T. J. Stalker, L. F. Brass, J. L. Daniel, D. Kitamura, and S. P. Kunapuli Hematopoietic lineage cell specific protein 1 (HS1) is a functionally important signaling molecule in platelet activation Blood, October 1, 2007; 110(7): 2449 - 2456. [Abstract] [Full Text] [PDF]

				B. Ibanez, G. Vilahur, and J. J. Badimon Pharmacology of thienopyridines: rationale for dual pathway inhibition Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G3 - G9. [Abstract] [Full Text] [PDF]

				M. P. Abbracchio, G. Burnstock, J.-M. Boeynaems, E. A. Barnard, J. L. Boyer, C. Kennedy, G. E. Knight, M. Fumagalli, C. Gachet, K. A. Jacobson, et al. International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy Pharmacol. Rev., September 1, 2006; 58(3): 281 - 341. [Abstract] [Full Text] [PDF]

				V. Schulte, H. P. Reusch, M. Pozgajova, D. Varga-Szabo, C. Gachet, and B. Nieswandt Two-Phase Antithrombotic Protection After Anti-Glycoprotein VI Treatment in Mice Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1640 - 1647. [Abstract] [Full Text] [PDF]

				B. Hechler, C. Nonne, E. J. Roh, M. Cattaneo, J.-P. Cazenave, F. Lanza, K. A. Jacobson, and C. Gachet MRS2500 [2-Iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a Potent, Selective, and Stable Antagonist of the Platelet P2Y1 Receptor with Strong Antithrombotic Activity in Mice J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 556 - 563. [Abstract] [Full Text] [PDF]

				D. Ferrari, A. la Sala, E. Panther, J. Norgauer, F. Di Virgilio, and M. Idzko Activation of human eosinophils via P2 receptors: novel findings and future perspectives J. Leukoc. Biol., January 1, 2006; 79(1): 7 - 15. [Abstract] [Full Text] [PDF]

				B. Hechler, S. Magnenat, M. L. Zighetti, M. U. Kassack, H. Ullmann, J.-P. Cazenave, R. Evans, M. Cattaneo, and C. Gachet Inhibition of Platelet Functions and Thrombosis through Selective or Nonselective Inhibition of the Platelet P2 Receptors with Increasing Doses of NF449 [4,4',4'',4'''-(Carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic Acid Octasodium Salt] J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 232 - 243. [Abstract] [Full Text] [PDF]

				C. Leon, M. Alex, A. Klocke, E. Morgenstern, C. Moosbauer, A. Eckly, M. Spannagl, C. Gachet, and B. Engelmann Platelet ADP receptors contribute to the initiation of intravascular coagulation Blood, January 15, 2004; 103(2): 594 - 600. [Abstract] [Full Text] [PDF]

				C. Leon, C. Ravanat, M. Freund, J.-P. Cazenave, and C. Gachet Differential Involvement of the P2Y1 and P2Y12 Receptors in Platelet Procoagulant Activity Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1941 - 1947. [Abstract] [Full Text] [PDF]

				M. Cattaneo, M. L. Zighetti, R. Lombardi, C. Martinez, A. Lecchi, P. B. Conley, J. Ware, and Z. M. Ruggeri Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding PNAS, February 18, 2003; 100(4): 1978 - 1983. [Abstract] [Full Text] [PDF]

				P. Nurden, C. Poujol, J. Winckler, R. Combrie, N. Pousseau, P. B. Conley, S. Levy-Toledano, A. Habib, and A. T. Nurden Immunolocalization of P2Y1 and TPalpha receptors in platelets showed a major pool associated with the membranes of alpha -granules and the open canalicular system Blood, February 15, 2003; 101(4): 1400 - 1408. [Abstract] [Full Text] [PDF]

				E. J. Weiss, J. R. Hamilton, K. E. Lease, and S. R. Coughlin Protection against thrombosis in mice lacking PAR3 Blood, October 16, 2002; 100(9): 3240 - 3244. [Abstract] [Full Text] [PDF]

				Genetically Modified Animals in Endocrinology Endocr. Rev., August 1, 2002; 23(4): 594 - 597. [Full Text] [PDF]

				D. Woulfe, H. Jiang, R. Mortensen, J. Yang, and L. F. Brass Activation of Rap1B by Gi Family Members in Platelets J. Biol. Chem., June 21, 2002; 277(26): 23382 - 23390. [Abstract] [Full Text] [PDF]